Inactief instrument

Koers Relypsa Inc

Aandelen

US7595311066

Biotechnologie & Medisch Onderzoek

slotkoers Nasdaq Andere beurzen
- ^USD	-

Nieuws in andere talen over Relypsa Inc

Relypsa : Announces Publication of Results of Veltassa Drug-Drug Interaction Studies in Journal of Cardiovascular Pharmacology and Therapeutics	13-02-17
Relypsa Announces Data on the Treatment and Impact of Hyperkalemia to be Presented at ASN Kidney Week 2016	03-11-16
Relypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia	30-08-16
Relypsa : Acquisition May Not Be in the Best Interests of RLYP Shareholders	25-07-16
RELYPSA, INC. Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Galenica May Be Unfair to Shareholders	22-07-16

Managers en directeuren - Relypsa Inc

Managers	Titel	Leeftijd	Van
David Bushinsky PRN	Corporate Officer/Principal	-	-
Gregory Oakes PRN	Corporate Officer/Principal	56	-

Bedrijfsprofiel

Sector

Biotechnologie & Medisch Onderzoek

Meer informatie over het bedrijf

Sector Biotherapeutische geneesmiddelen

	Vaira. 1 jan.	Kapi.
VERTEX PHARMACEUTICALS INCORPORATED	-0,49%	105 mld.
REGENERON PHARMACEUTICALS, INC.	+3,31%	97,5 mld.
ARGENX SE	+2,91%	22,19 mld.
BIONTECH SE	-16,16%	21,33 mld.
GENMAB A/S	-7,24%	18,68 mld.
WUXI APPTEC CO., LTD.	-41,41%	16,6 mld.
BEIGENE, LTD.	-22,87%	14,52 mld.
NEUROCRINE BIOSCIENCES, INC.	+6,32%	14,09 mld.
SAREPTA THERAPEUTICS, INC.	+21,46%	10,99 mld.

Biotherapeutische geneesmiddelen

Handhaaf en verhoog de prestaties van je beleggingen met ons team van experts aan jouw zijde

Mijn beleggingen veiligstellen

fermer